Disposable-Syringe Jet Injector for Measles-Mumps-Rubella vaccine (DSJI MMR) study

ISRCTN ISRCTN04280032
DOI https://doi.org/10.1186/ISRCTN04280032
Protocol serial number Asclin/002/2009
Sponsor Bio-Manguinhos/Fiocruz (Brazil)
Funders Bill and Melinda Gates Foundation (USA) - PATH DSJI project, Bio-Manguinhos/Fiocruz (Brazil)
Submission date
08/07/2010
Registration date
29/07/2010
Last edited
10/07/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Reinaldo Martins
Scientific

Av. Brasil 4365
Manguinhos
Rio de janeiro
21040-360
Brazil

Phone +55 21 3882 9497
Email rmenezes@bio.fiocruz.br

Study information

Primary study designInterventional
Study designRandomised controlled non-inferiority study
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleA randomised, non-inferiority study comparing safety and immunogenicity of a disposable-syringe jet injector to needle and syringe for the administration of measles-mumps-rubella combination vaccine to healthy Brazilian infants aged 12 to 18 months
Study acronymDSJI/MMR
Study objectivesImmunogenicity of measles-mumps-rubella (MMR) vaccine administered by needle free device is non inferior to that induced by needle and syringe.
Ethics approval(s)Approved on 4th April 2010 by:
1. PATH REC (ref: 499)
2. Brazilian CONEP National Ethics Committee (ref: 15810)
Health condition(s) or problem(s) studiedMeasles, mumps and rubella vaccination
InterventionMMR vaccine, against measles, mumps and rubella (Schwarz, RIT 4385 and Wistar RA 27/3 strains, respectively), to be administered as a single 0.5 mL dose, subcutaneously, delivered by a needle-free device (experimental group) or by the conventional needle and syringe method (control group), in a 2:1 proportion,
that is, 388 volunteers allocated to the experimental group and 194 to the control group. Volunteers will be followed-up for 42 days after vaccination. Blood collections for immunogenicity before vaccination and 42 days after vaccination. Adverse events will be registered in diary cards by parents/guardians during this period.
Intervention typeDrug
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Measles-mumps-rubella vaccine
Primary outcome measure(s)

Antibody titres 42 days after vaccination: cut offs for enzyme-linked immunosorbent assay (ELISA) 231 units/mL (mumps) and 4 IU/mL for rubella. Plaque reduction neutralisation test (PRNT) for measles, cut off 0.20 IU/mL.

Key secondary outcome measure(s)

Local and systemic adverse events during 42 days after vaccination

Completion date26/07/2011

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit12 Months
Upper age limit18 Months
SexAll
Target sample size at registration582
Total final enrolment582
Key inclusion criteria1. Healthy children from 12 to 18 months of age, either sex
2. Up-to-date with their immunisation schedule according to age
3. Not enrolled in other clinical studies
Key exclusion criteria1. Parents/guardians unable or unwilling to give consent for the study
2. Unable to follow the study procedures
Date of first enrolment26/07/2010
Date of final enrolment26/07/2011

Locations

Countries of recruitment

  • Brazil

Study participating centre

Av. Brasil 4365
Rio de janeiro
21040-360
Brazil

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/03/2015 10/07/2019 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

10/07/2019: Publication reference and total final enrolment added.